Press releases. October 24 2024 GSK invests up to $800 million in Pennsylvania site, largest manufacturing investment in U.S. October 24 2024 New data for AREXVY, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease. October 16 2024 ViiV Healthcare shows more ...
GSK is the tenth largest pharmaceutical company and No. 294 on the 2022 Fortune Global 500, ranked behind other pharmaceutical companies China Resources, Sinopharm, Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis, Bayer, and Merck Sharp & Dohme.
We are a focused biopharma company with strong momentum and big ambitions, to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. [4][5] The company's product portfolio includes prescription medicines and vaccines.
Our legacy companies developed a variety of medicines and vaccines that helped to form the building blocks of today’s GSK - a biopharma company that has grown from a handful of individual founders into a company of 70,000 people. Glaxo packing …
GSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions. We employ ~15,000 people across the US and have two corporate hubs. Explore GSK in the US.
At a glance. Getting Ahead Together means preventing disease as well as treating it. Globally, our portfolio spans vaccines, specialty and general medicines, with R&D focused on science of the immune system, human genetics and advanced technologies.
Get the latest GSK plc (GSK) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.